Has Anyone Gotten Thyroid Cancer from Mounjaro? What the Evidence Actually Shows

Where the thyroid cancer concern actually came from

The worry did not emerge from a patient. It came from the laboratory. During pre-approval animal testing, rodents given tirzepatide developed C-cell tumours in the thyroid, a type associated with medullary thyroid carcinoma. That sounds alarming, but regulators and the researchers who reviewed the data noted a crucial limitation: rodent thyroid C-cells express GIP and GLP-1 receptors at much higher densities than human C-cells do. The biological mechanism that drove tumour growth in rats is not thought to operate in the same way in human thyroid tissue. The NHS tirzepatide medicines page outlines what is currently known about Mounjaro's side-effect profile without flagging thyroid cancer as a confirmed human risk. Regulatory bodies in the UK and elsewhere reviewed all available preclinical data before granting a licence, and if you want to understand how tirzepatide's relationship with thyroid cancer developed from those animal studies through to current guidance, that background helps explain why the warning exists in the form it does. That distinction matters.

So the answer to whether anyone has gotten thyroid cancer from Mounjaro is: not in a way that has been causally attributed to the medicine in the published trial data or post-marketing reports available as of mid-2026. The SURMOUNT clinical programme involved thousands of adults. Thyroid malignancy was not identified as a treatment-related adverse event in those trials.

Who this warning applies to directly, and why they should not take Mounjaro

The precautionary language in the prescribing information is not merely advisory for one group: people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2) should not take Mounjaro. This is a clear contraindication, and it is one of the first things a prescriber checks. It is also why genuine clinical assessment before prescribing matters so much. An online form that skips your family medical history, or a seller who ships without a prescription, cannot make that check. For more on how the thyroid concern fits into the broader safety picture, our detailed look at Mounjaro and thyroid cancer risk covers the regulatory position and what monitoring means in practice.

For everyone else (people without that personal or family history) the risk profile looks different. The clinical trials did not find evidence that tirzepatide caused thyroid cancer in participants without pre-existing susceptibility. That does not mean ongoing surveillance is unnecessary; it means the current evidence base does not support the fear that taking Mounjaro will give an otherwise healthy person thyroid cancer.

Symptoms that should prompt you to get medical advice quickly

Regardless of what the statistics say at a population level, any change you notice in your own body while on treatment deserves attention. If you develop a new lump or swelling at the front of your neck, persistent hoarseness, difficulty swallowing, or a feeling of something pressing on your windpipe, contact your GP or a medical professional the same day. These are not signs that Mounjaro has definitely caused anything, but they are symptoms that warrant investigation whatever their cause. The relationship between Mounjaro and thyroid function more broadly is a separate question from cancer risk, and worth understanding if you have an existing thyroid condition such as hypothyroidism. You can also report any suspected side effect, including unexpected changes in your neck or thyroid area, through the MHRA Yellow Card scheme, it is open to patients as well as healthcare professionals, and reports like yours contribute to the evidence base that keeps prescribing guidance current.

How a prescriber weighs this at your consultation

This is ultimately a clinical decision, not a general one. A prescriber reviewing your case for Mounjaro will ask about your personal and family medical history, and how Mounjaro interacts with thyroid health specifically is one area they will consider alongside endocrine syndromes and relevant comorbidities. They will also consider whether the benefits of treatment for your weight and health are proportionate to any individual risk factors you carry. Our clinical team, which you can read about on the clinical team profile, reviews every consultation personally before any prescription is issued. If there is anything in your history that gives pause, they will say so, and suggest alternatives or specialist referral as appropriate. For a fuller picture of what the percentage figures from trials actually show, that page sets the numbers in context without overstating them. If you are ready to have the conversation with a prescriber, start your free consultation and your answers will be reviewed the same day by a GPhC-registered Independent Prescriber, not automated software.